18460821. NITROGEN-CONTAINING HETEROCYCLIC AMIDE COMPOUND AND PHARMACEUTICAL USE THEREOF simplified abstract (Japan Tobacco Inc.)
NITROGEN-CONTAINING HETEROCYCLIC AMIDE COMPOUND AND PHARMACEUTICAL USE THEREOF
Organization Name
Inventor(s)
Nobutaka Yamaoka of Osaka (JP)
NITROGEN-CONTAINING HETEROCYCLIC AMIDE COMPOUND AND PHARMACEUTICAL USE THEREOF - A simplified explanation of the abstract
This abstract first appeared for US patent application 18460821 titled 'NITROGEN-CONTAINING HETEROCYCLIC AMIDE COMPOUND AND PHARMACEUTICAL USE THEREOF
The present invention offers a compound with PDHK inhibitory activity for treating diabetes, insulin resistance syndrome, metabolic syndrome, and other related conditions.
- Compound with PDHK inhibitory activity
- Treatment or prophylaxis of diabetes, insulin resistance syndrome, metabolic syndrome, hyperglycemia, and more
- Useful for diabetic complications, cardiac issues, dyslipidemia, atherosclerosis, and other conditions
- Includes a compound of specific formulas or their pharmaceutically acceptable salts
- Potential Applications:**
The compound can be used in the treatment of various diabetes-related conditions, cardiac issues, dyslipidemia, atherosclerosis, and more.
- Problems Solved:**
This technology addresses the need for effective treatments for diabetes, insulin resistance syndrome, metabolic syndrome, and related health issues.
- Benefits:**
The compound offers potential benefits in managing diabetes, improving cardiac health, addressing dyslipidemia, and combating atherosclerosis.
- Commercial Applications:**
The compound can be developed into pharmaceutical products for diabetes treatment, cardiac health improvement, and dyslipidemia management, presenting significant market opportunities.
- Prior Art:**
Researchers can explore existing literature on PDHK inhibitory compounds and their applications in treating diabetes and related conditions.
- Frequently Updated Research:**
Stay informed about the latest studies on PDHK inhibitory compounds and their potential impact on diabetes treatment and cardiac health.
- Questions about PDHK Inhibitory Compound:**
1. What are the specific mechanisms through which the compound inhibits PDHK activity? 2. How does the compound compare to existing treatments for diabetes and related conditions?
Original Abstract Submitted
The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension or Alzheimer disease. The present invention relates to a compound of the formula [I-a] or the formula [II], or a pharmaceutically acceptable salt thereof: